I’ve been digging into micro-caps that got completely obliterated over the last couple of years by the macro downturn in biotech and the Buffett style of investing (buying unloved businesses backed by heavy cash piles and massive safety margins).
Most of wall street has walked away because it looks unprofitable, but if you look at the actual asset to valuation disconnect, the risk/reward over a 2–5 year horizon is crazy skewed.
- The market cap is roughly $320 million.
Cash & Marketable Securities: $111.7 million
Total Debt: $0
Given that, enterprise value is roughly $210 million and in Q1 2026, they used less than $1.5 million operationally.
- Mid-50s Gross Margins
908 Devices makes handheld chemical/molecular analysis tools (used by forensics, state/local law enforcement for fentanyl detection, and biopharma).
Their GAAP gross margin is 51%, and their Adjusted Gross Margin just expanded to 57% in Q1 2026.
High-50s gross margins are proof of structural pricing power. People don't buying on price but because the technology is highly differentiated and hard to replicate.
-
They just crossed 3,900 cumulative device placements globally. Total revenue for Q1 was $13.4 million (up 14% YoY), but recurring revenue (consumables, service contracts) made up 30% of that ($4 million).
-
The 2-5 Year Catalysts for Re-Rating
I believe the company is executing a turnaround from unscaleable tech into cash generation.
Management just raised full-year 2026 revenue guidance to $67M–$70M, representing 19% to 25% YoY growth.
Once the macro cycle normalizes and the company hits consistent positive cash flow over the next few years, the market will easily re-rate this back to a normalized multiple.
Would love to hear if anyone else has looked at this one or sees any red flags I missed.